2006 MIT $100K Business Plan Winner - Semprus BioSciences - Hosts Final Judging Round for 2011 Life Sciences Competitors
Cambridge, MA, April 30, 2011 --(PR.com)-- Semprus BioSciences today announced it will host the final round of judging for the Life Sciences Track of the 2011 MIT $100K Entrepreneurship Competition on Monday, May 2. The five finalist teams will pitch their business plans to a judging panel that includes Semprus Chief Technology Officer Christopher R. Loose and representatives from the competition.
In 2006, Loose and Chief Executive Officer David L. Lucchino were the Robert P. Goldberg Grand Prize winners of the MIT $100K Competition, comprising 130 teams. They have since transformed Semprus into a 27-person company that has raised a total of $28.5M in equity financing.
The MIT $100K Entrepreneurship Competition is a year-long educational experience designed to encourage MIT students to act on their talent, ideas, and energy to produce tomorrow's leading firms. More than 5,000 MIT students and colleagues have competed in the $100K since it began in 1990. Hundreds of companies have launched since then, including Semprus BioSciences, and more than a dozen have grown past the $100M revenue mark.
“The MIT $100K Entrepreneurship Competition is always thrilled to have the support and cooperation of young enterprises,” said John Casey, assistant director of the MIT $100K. “We're even more excited when we can say that a partner is not only a product of MIT, but is also a former $100K winner. In that we're very appreciative to Semprus both for facilitating the 2011 Business Plan Contest and for inspiring students such as our contestants and ourselves to reach such success.”
“Kendall Square is one of the few places on the globe where innovation is being driven by an open and collaborative network of scientists, business professionals and engineers,” Lucchino said. “My co-founders, MIT Institute Professor Robert Langer, Sc.D., and Semprus CTO Chris Loose, Ph.D., and I are proud to help propel the innovation cycle for aspiring entrepreneurs at MIT. Anytime we have the opportunity to give back to the MIT community, we jump at the chance.”
Semprus BioSciences is a venture-backed biomedical company with a dual mission: to provide complication free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies. The company’s current focus is to develop a vascular access catheter with the first single surface modification that is designed to simultaneously reduce microbial adherence and thrombus accumulation over the life of the device. The company spun out of the labs of biomedical researcher and Massachusetts Institute of Technology (MIT) Professor Robert Langer, Sc.D., in 2007.
About Semprus BioSciences
Semprus BioSciences is a venture-backed biomedical company headquartered in Cambridge, Massachusetts. The company’s innovative, multi-faceted Semprus technology signifies a breakthrough in medical device technology. Its current focus is to develop a vascular access catheter with the first single surface modification that is designed to simultaneously reduce microbial adherence and thrombus accumulation over the life of the device. In December 2010, the company completed an $18 million Series B financing coled by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners (FMP), a national healthcare venture capital investment firm with a strategic relationship with Cleveland Clinic. Combined with previous financing rounds, Semprus has raised a total of $28.5 million in equity.
Visit http://www.semprusbio.com for additional information.
Semprus BioSciences won Frost & Sullivan’s“2010 North American Enabling Technology of the Year Award for Surface in Functionalization Technologies” for its Semprus Platform in December 2010.
Semprus BioSciences was selected as one of “50 Companies to Watch” by Medical Devices & Diagnostics Industry magazine in June 2010.
Contact: Michael Devine
m.devine@semprusbio.com
617.577.7755 ext. 202
Holly P. Glass
holly.glass@semprusbio.com
571.243.1952
###
In 2006, Loose and Chief Executive Officer David L. Lucchino were the Robert P. Goldberg Grand Prize winners of the MIT $100K Competition, comprising 130 teams. They have since transformed Semprus into a 27-person company that has raised a total of $28.5M in equity financing.
The MIT $100K Entrepreneurship Competition is a year-long educational experience designed to encourage MIT students to act on their talent, ideas, and energy to produce tomorrow's leading firms. More than 5,000 MIT students and colleagues have competed in the $100K since it began in 1990. Hundreds of companies have launched since then, including Semprus BioSciences, and more than a dozen have grown past the $100M revenue mark.
“The MIT $100K Entrepreneurship Competition is always thrilled to have the support and cooperation of young enterprises,” said John Casey, assistant director of the MIT $100K. “We're even more excited when we can say that a partner is not only a product of MIT, but is also a former $100K winner. In that we're very appreciative to Semprus both for facilitating the 2011 Business Plan Contest and for inspiring students such as our contestants and ourselves to reach such success.”
“Kendall Square is one of the few places on the globe where innovation is being driven by an open and collaborative network of scientists, business professionals and engineers,” Lucchino said. “My co-founders, MIT Institute Professor Robert Langer, Sc.D., and Semprus CTO Chris Loose, Ph.D., and I are proud to help propel the innovation cycle for aspiring entrepreneurs at MIT. Anytime we have the opportunity to give back to the MIT community, we jump at the chance.”
Semprus BioSciences is a venture-backed biomedical company with a dual mission: to provide complication free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies. The company’s current focus is to develop a vascular access catheter with the first single surface modification that is designed to simultaneously reduce microbial adherence and thrombus accumulation over the life of the device. The company spun out of the labs of biomedical researcher and Massachusetts Institute of Technology (MIT) Professor Robert Langer, Sc.D., in 2007.
About Semprus BioSciences
Semprus BioSciences is a venture-backed biomedical company headquartered in Cambridge, Massachusetts. The company’s innovative, multi-faceted Semprus technology signifies a breakthrough in medical device technology. Its current focus is to develop a vascular access catheter with the first single surface modification that is designed to simultaneously reduce microbial adherence and thrombus accumulation over the life of the device. In December 2010, the company completed an $18 million Series B financing coled by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners (FMP), a national healthcare venture capital investment firm with a strategic relationship with Cleveland Clinic. Combined with previous financing rounds, Semprus has raised a total of $28.5 million in equity.
Visit http://www.semprusbio.com for additional information.
Semprus BioSciences won Frost & Sullivan’s“2010 North American Enabling Technology of the Year Award for Surface in Functionalization Technologies” for its Semprus Platform in December 2010.
Semprus BioSciences was selected as one of “50 Companies to Watch” by Medical Devices & Diagnostics Industry magazine in June 2010.
Contact: Michael Devine
m.devine@semprusbio.com
617.577.7755 ext. 202
Holly P. Glass
holly.glass@semprusbio.com
571.243.1952
###
Contact
Semprus BioSciences
Michael Devine
(617) 577-7755
http://www.semprusbio.com
Michael Devine
(617) 577-7755
http://www.semprusbio.com
Contact
Categories